Loading...
•
Sep 30, 2021
Protagonist Q3 2021 Earnings Report
Reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.
Key Takeaways
Protagonist Therapeutics reported progress in its clinical programs, including proof-of-concept data for rusfertide in hereditary hemochromatosis and the resumption of rusfertide clinical studies following the resolution of an FDA clinical hold. PN-235 is advancing into a Phase 2 study in psoriasis in early 2022.
Resumed Phase 2 study of rusfertide in polycythemia vera after FDA clinical hold removal.
Presented positive proof-of-concept data for rusfertide in hereditary hemochromatosis at The Liver Meeting®.
PN-235 is moving into a psoriasis indication, with Phase 2 study initiation planned for early 2022.
PN-943 Phase 2 study for ulcerative colitis is underway with data readout expected in Q2 2022.
Protagonist
Protagonist
Forward Guidance
Protagonist Therapeutics is advancing its clinical programs and anticipates key milestones in the near term.